SAB Biotherapeutics is trading at $2.75, up 5.77%, with broad biotech strength potentially supporting the move. - The XBI rose 2.10% during the regular session. - No new company-specific announcement explaining the October 20 advance was identified. Chardan conference participation was announced October 14, so it is not a fresh catalyst. - The FDA Fast Track designation for SAB-142 was announced October 13, not October 20.